Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 1/20 | 0.80 |
| ▸ | CDK4 | P11802 | 11/20 | 0.78 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.78 |
| ▸ | CCND1 | P24385 | 11/20 | 0.78 |
| ▸ | CDK2 | P24941 | 11/20 | 0.78 |
| ▸ | CCND3 | P30281 | 11/20 | 0.78 |
| ▸ | JAK2 | O60674 | 5/20 | 0.77 |
| ▸ | JAK1 | P23458 | 5/20 | 0.77 |
| ▸ | TYK2 | P29597 | 5/20 | 0.77 |
| ▸ | JAK3 | P52333 | 5/20 | 0.77 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.73 |
| ▸ | KDR | P35968 | 4/20 | 0.73 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.71 |
| ▸ | FLT1 | P17948 | 1/20 | 0.71 |
| ▸ | CDK1 | P06493 | 1/20 | 0.67 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3537965 | 0.89 | ITK (0.76) | ITKCDK4CCNA2CCND1CDK2 | |
| SCHEMBL5254386 | 0.88 | CDK4 (1.00) | ITKCDK4CCNA2CCND1CDK2 | |
| SCHEMBL5246946 | 0.87 | CDK4 (1.00) | ITKCDK4CCNA2CCND1CDK2 | |
| SCHEMBL3532060 | 0.84 | CHEK1 (0.79) | CDK4CCNA2CCND1CDK2CCND3 | |
| SCHEMBL29714859 | 0.84 | FGFR1 (1.00) | ITKCDK4CCNA2CCND1CDK2 | |
| SCHEMBL311148 | 0.84 | FGFR1 (1.00) | ITKCDK4CCNA2CCND1CDK2 | |
| SCHEMBL3543632 | 0.83 | FGFR1 (0.71) | ITKCDK4CCNA2CCND1CDK2 | |
| SCHEMBL3533781 | 0.83 | FGFR1 (0.71) | ITKCDK4CCNA2CCND1CDK2 | |
| SCHEMBL3537031 | 0.83 | FGFR1 (0.71) | ITKCDK4CCNA2CCND1CDK2 | |
| SCHEMBL3534644 | 0.83 | FGFR1 (0.71) | ITKCDK4CCNA2CCND1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674823-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20070238729-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-7226918-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| US-7064215-B2 | Indazole benzimidazole compounds | CHIRON CORPORATION (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
| US-20040192687-A1 | Dna-pk inhibitors | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2004-09-30 | — | — | US | disclosed |
| EP-1417196-A1 | DNA-PK INHIBITORS | Cancer Research Technology Limited (GB) | 2004-05-12 | — | — | EP | disclosed |
| EP-1401831-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030207883-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2003024949-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003004488-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079564-A1 | Indazole benzimidazole compounds | ABL1, ABL2, ALK | ITK 1055/4885CDK4 646/4885CCNA2 3156/4885 |
| US-20040192687-A1 | Dna-pk inhibitors | ATM, CHEK1, XRCC6 | ITK 408/4885CDK4 122/4885CCNA2 1161/4885 |
| US-20070238729-A1 | DNA-PK INHIBITORS | ATM, CHEK2, CHEK1 | ITK 236/4885CDK4 39/4885CCNA2 610/4885 |
| US-20030207883-A1 | Indazole benzimidazole compounds | SLCO1B3, SLCO1B1, SLCO4C1 | ITK 855/4885CDK4 1387/4885CCNA2 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.